mounjaro

A man in Gurgaon was allegedly producing fake mounjaro injections and selling his own unapproved brand, 'Toneup', disguised as a Japanese product. Authorities recalled 22 Toneup injections after tracing sales to multiple cities. The accused learned to make injections using online resources and sourced materials from China.

Experiencing hair loss while losing weight is a common physiological reaction as the body enters 'survival mode.' Rapid weight loss, often triggered by extreme diets or weight-loss medications, can push hair follicles into a resting phase. Let's know more about this issue.

As young and otherwise healthy people turn to GLP-1 drugs to meet weight targets, doctors warn the side-effects can land them in hospital

Authorities have uncovered a dual operation in Gurgaon where a man manufactured fake mounjaro injections and an unapproved tirzepatide-based product named 'Toneup'. Using 3D printing for packaging, he sold these counterfeit and unapproved vials online, with some traced to buyers in Delhi and Hyderabad. The investigation is ongoing, and an immediate recall has been initiated.

Raw Material Source Tracked, Flat In Gurgaon Used to Assemble Injections

Rapid weight loss from mounjaro can lead to a phenomenon dubbed 'mounjaro face,' characterised by hollowed cheeks, prominent lines, and skin looseness. Experts advise a slower weight loss pace, adequate protein, and consistent skincare to mitigate these visible facial changes. Nutritional support and hydration are also crucial for skin health during this process.

It is not a quick fix. It is not your ‘next-generation weight-loss drug’. It is not a cosmetic solution or something to include in a pre-wedding routine, experts warn. Despite that, the popularity of mounjaro continues to quietly reshape the narrative around fitness, beauty and confidence

In a significant crackdown in Gurgaon, law enforcement dismantled a counterfeit drug operation, arresting two suspects with illicit mounjaro KwikPen injections worth over ₹70 lakh. Investigators found serious labeling flaws and that the injections were improperly stored, deviating from the required 2°C to 8°C temperature range. The seized goods included dosages ranging from 2.

Affordable generic versions of Ozempic and Wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging Eli Lilly's mounjaro, with generics and lower pricing boosting semaglutide's market position.

New research reveals genes influence weight loss and nausea from Ozempic and mounjaro. A study of nearly 28,000 people found specific genetic variants predict drug effectiveness and side effects. This breakthrough could lead to personalized prescriptions, helping doctors tailor treatments for millions. Doctors may soon use genetic tests to set realistic expectations and choose the best drug for each patient.

An Instagram reel sparks a deep dive into weight-loss peptides, leading many in India to import unapproved, trial-stage medications from China. Driven by cost and the desire to overcome weight-loss plateaus, individuals are navigating AI-simplified science and online communities to obtain these substances, bypassing official medical channels.

Influencers and online communities are driving a surge in unapproved weight-loss peptides imported from China. This trend is fueled by the high cost of doctor-prescribed medications and the desire to overcome weight-loss plateaus, as the body can adapt to even potent GLP-1 drugs, leading to weight regain.

The UAE has approved Foundayo (orforglipron), Eli Lilly's once-daily oral obesity pill, becoming one of the first countries globally to offer a needle-free alternative. This GLP-1 receptor agonist mimics natural hormones to regulate appetite and blood sugar, aiding weight loss and improving metabolic health. Available by prescription from May 2026, it's intended for long-term use alongside lifestyle changes.

Online forums are leading Indians to experimental weight-loss drugs not yet approved for use. What follows is a murky chain of Chinese suppliers, local sellers, imports and self-injection that has doctors worried

An Indian man hailed mounjaro as a "miracle" for losing 10 kilos in three months, but revealed a concerning side effect: emotional blunting. He described feeling muted joy and sadness, impacting his personal and professional life. While the drug effectively suppresses appetite, he felt a crucial emotional switch had been turned off, a rarely discussed consequence beyond typical side effects.

Actress Bhumi Pednekar now prioritizes her health over film roles, acknowledging her body's changing needs with age. She revealed her significant weight loss journey, emphasizing a decade of dedication to fitness and healthy eating, dispelling misconceptions about quick fixes. Pednekar stressed staying true to one's craft over fleeting relevance in the industry.

As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships

Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. Torrent Pharma even introduced both oral and injectable versions, marking a significant step in addressing India's growing metabolic disorder crisis.

New research suggests we’re on the cusp of a pharmacological shortcut to spiritual detachment. But is this the enlightenment we've been waiting for, or just a cheat code for the soul?

Doctors in Hyderabad are alarmed by the unsupervised use of diabetes and weight-loss drugs like Ozempic for cosmetic purposes, driven by social media and peer influence. Concerns are rising as cheaper generic versions are set to launch, potentially increasing misuse and leading to serious side effects without medical supervision.

mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight management and diabetes treatment. Offering a dual-action mechanism targeting GLP-1 and GIP receptors, it has shown potential benefits over Ozempic and is now available in India at a significantly lower cost.